An2 Therapeutics Inc (ANTX) Stock Price, Quote & News

Company Profile

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chag...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 331 9090

Website: www.an2therapeutics.com

Address:

1800 El Camino Real, Suite D, Menlo Park, United States

OfficialStocktwitsUser Feb. 19 at 6:02 PM

$ANTX RSI: 26.09, MACD: -0.0336 Vol: 0.06, MA20: 1.11, MA50: 1.14 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

DriftRunner Feb. 18 at 9:53 AM

$ANTX Oncology biotech with early-stage risk profile.

0 · Reply

PortfolioParagon Feb. 17 at 12:58 PM

$ANTX Pre-revenue biotech; early-stage.

0 · Reply

silentgabe Feb. 17 at 8:40 AM

$ANTX Pre-revenue biotech; early-stage

0 · Reply

FusionFuturist Feb. 9 at 2:59 PM

$ANTX Neurology or pain therapeutic; CNS development carries high failure rates.

0 · Reply

NVDAMillionaire Feb. 4 at 5:35 PM

$ANTX Outstanding article that hits the mark on ANTX's current state. So if you want to refresh your ANTX insights or learn about ANTX from scratch, this is a must read. https://everyticker.com/quote/ANTX/analysis/an2-therapeutics-boron-chemistry-s-last-stand-at-1-20-nasdaq-antx

0 · Reply

OfficialStocktwitsUser Jan. 30 at 4:04 PM

$ANTX RSI: 39.55, MACD: 0.0056 Vol: 0.07, MA20: 1.19, MA50: 1.14 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

THSSKS Jan. 13 at 4:14 PM

$ANTX still over $2/share cash. They should unwind and look for strategic alternatives

0 · Reply

TheRealShortSqueezy Jan. 12 at 8:40 PM

$HYFT: Cup & Handle Breakout in Play 🚨‼️ MindWalk Holdings Corp is forming a classic cup and handle pattern, a bullish setup that often signals trend continuation. After an extended consolidation, price has reclaimed key resistance in the $2.50–$2.65 zone, suggesting renewed strength. Technical highlights: 📈Clear cup and handle formation on the daily chart 📈Breakout above prior resistance with solid follow-through 📈Higher-low structure signaling improving demand 📈Measured move upside targets near $3.60 → $4.40 → $4.90 Adding to the setup, MindWalk announced a share repurchase program on Oct 9, 2025, a shareholder-friendly catalyst that could help tighten supply as price approaches higher levels. If volume continues to support the move, HYFT may be entering a new bullish leg, with momentum traders watching closely as the pattern develops. Communicated Disclaimer: https://bit.ly/45yIR8a Sector Peers: $CRSP $IGMS $ANTX $CABA

1 · Reply

TheRealShortSqueezy Jan. 12 at 2:21 PM

📌 $HYFT : Weekly Chart Setting Up for Expansion MindWalk holdings is pressing into key weekly resistance near $3.25, aligning with the cup level on the weekly timeframe and signaling growing upside potential. 🔍 Weekly structure highlights: 🔹 Price is firmly challenging the $3.25 weekly cup level 🔹 Strong recovery from long term lows with clear higher-low structure 🔹 Momentum accelerating as price moves through the base 🎯 Upside levels in focus as momentum builds: 📈 $3.65 📈 $4.00 📈 $4.40 📈 $4.90 📈 $5.43 📈 $5.90–$6.50 zone A sustained push through $3.25 on the weekly sets the stage for a broader move higher, with the chart offering clear expansion potential into upper resistance bands. Positive market reaction to recent breakthroughs reinforces HYFT’s positioning as a potential platform winner in the multi billion dollar influenza vaccine market. Communicated Disclaimer: https://bit.ly/45yIR8a Sector Peers: $IGMS $ANTX $CABA $ENTX

0 · Reply

AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 5 weeks ago

AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease

Nov 12, 2025, 4:01 PM EST - 3 months ago

AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights

Nov 10, 2025, 7:00 AM EST - 3 months ago

AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)

Nov 6, 2025, 5:03 PM EST - 3 months ago

AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference

Aug 12, 2025, 4:01 PM EDT - 6 months ago

AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights

Aug 12, 2025, 7:00 AM EDT - 6 months ago

AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease

Jul 23, 2025, 7:00 AM EDT - 7 months ago

AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease

Jun 30, 2025, 7:00 AM EDT - 8 months ago

AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole

May 29, 2025, 7:00 AM EDT - 9 months ago

AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference

May 13, 2025, 4:01 PM EDT - 10 months ago

AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights

May 1, 2025, 4:00 PM EDT - 10 months ago

AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline

Apr 30, 2025, 7:00 AM EDT - 10 months ago

AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference

Mar 25, 2025, 4:00 PM EDT - 11 months ago

AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights

Mar 3, 2025, 4:00 PM EST - 1 year ago

AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference

$AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease$

Feb 24, 2025, 7:00 AM EST - 1 year ago

AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease

Feb 20, 2025, 7:00 AM EST - 1 year ago

AN2 Therapeutics to Participate at Upcoming Investor Conferences

Jan 29, 2025, 4:00 PM EST - 1 year ago

AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Nov 13, 2024, 4:00 PM EST - 1 year ago

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

Oct 17, 2024, 7:00 AM EDT - 1 year ago

AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria

Aug 28, 2024, 4:00 PM EDT - 1 year ago

AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 16, 2024, 7:00 AM EDT - 1 year ago

AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

Aug 13, 2024, 4:01 PM EDT - 1 year ago

AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights

$AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease$

Aug 8, 2024, 4:30 PM EDT - 1 year ago

AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease

May 14, 2024, 4:01 PM EDT - 1 year ago

AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights

Mar 28, 2024, 4:10 PM EDT - 2 years ago

AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

Feb 12, 2024, 6:56 AM EST - 2 years ago

AN2 Therapeutics to pause lung disease study enrollment

$AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease$

Feb 12, 2024, 6:45 AM EST - 2 years ago

AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease

Jan 30, 2024, 4:10 PM EST - 2 years ago

AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference

Nov 9, 2023, 4:05 PM EST - 2 years ago

AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights

Nov 6, 2023, 7:00 AM EST - 2 years ago

AN2 Therapeutics to Present at Upcoming Investor Conferences

Oct 18, 2023, 7:00 AM EDT - 2 years ago

AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease

Oct 11, 2023, 12:01 AM EDT - 2 years ago

AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023

Sep 26, 2023, 7:00 AM EDT - 2 years ago

AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria

$AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease$

Sep 13, 2023, 7:00 AM EDT - 2 years ago

AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease

Aug 15, 2023, 10:42 PM EDT - 2 years ago

AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock

Aug 10, 2023, 4:10 PM EDT - 2 years ago

AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

May 25, 2023, 4:10 PM EDT - 2 years ago

AN2 Therapeutics to Present at Jefferies Healthcare Conference

May 11, 2023, 4:10 PM EDT - 3 years ago

AN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights

May 5, 2023, 1:55 PM EDT - 3 years ago

AN2 Therapeutics: Boron Chemistry For Infectious Diseases

May 1, 2023, 7:00 AM EDT - 3 years ago

AN2 Therapeutics to Present at JMP Securities Life Sciences Conference

Mar 29, 2023, 4:01 PM EDT - 3 years ago

AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

Feb 28, 2023, 4:10 PM EST - 3 years ago

AN2 Therapeutics to Participate in Upcoming Investor Conferences

Jan 31, 2023, 4:10 PM EST - 3 years ago

AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference

OfficialStocktwitsUser Feb. 19 at 6:02 PM

0 · Reply

DriftRunner Feb. 18 at 9:53 AM

$ANTX Oncology biotech with early-stage risk profile.

0 · Reply

PortfolioParagon Feb. 17 at 12:58 PM

$ANTX Pre-revenue biotech; early-stage.

0 · Reply

silentgabe Feb. 17 at 8:40 AM

$ANTX Pre-revenue biotech; early-stage

0 · Reply

FusionFuturist Feb. 9 at 2:59 PM

$ANTX Neurology or pain therapeutic; CNS development carries high failure rates.

0 · Reply

NVDAMillionaire Feb. 4 at 5:35 PM

0 · Reply

OfficialStocktwitsUser Jan. 30 at 4:04 PM

0 · Reply

THSSKS Jan. 13 at 4:14 PM

$ANTX still over $2/share cash. They should unwind and look for strategic alternatives

0 · Reply

TheRealShortSqueezy Jan. 12 at 8:40 PM

1 · Reply

TheRealShortSqueezy Jan. 12 at 2:21 PM

0 · Reply

DARKP00L Jan. 12 at 12:16 PM

$ANTX 07:10 on Jan. 12 2026 The FDA Clears Oregon Health & Science University's Investigational New Drug Application To Proceed With Investigator-Initiated Trial Of AN2 Therapeutics' Epetraborole For Mycobacterium Abscessus Lung Disease, Patient Enrollment To Start In Q1 2026 #tradeideas

0 · Reply

vcdc Jan. 12 at 12:12 PM

$ANTX FDA has cleared Oregon Health & Science University's, or OHSU, investigational new drug, or IND, application to proceed with an IIT that will evaluate the safety, efficacy, and pharmacokinetics of epetraborole in patients with Mycobacterium abscessus lung disease. https://www.businesswire.com/news/home/20260112479198/en/AN2-Therapeutics-%E2%80%BA-FDA-Clearance-to-Proceed-with-90-Patient-Investigator-Initiated-Trial-IIT-of-Epetraborole-in-Patients-with-M.-abscessus-Lung-Disease

0 · Reply

THSSKS Jan. 9 at 9:56 AM

$ANTX $1 should be the bottom here. Looking for at least $2 going to phase 1 data. Well over $2/share alone. 12-21 months of cash burn left.

0 · Reply

Sw1ngb0t Jan. 9 at 4:40 AM

$ANTX $1.54+

0 · Reply

BullishBee Jan. 8 at 8:44 PM

We didn't just catch $ANTX once today, we caught it twice. The AI Model signaled a separate entry at 12:02 PM and squeezed even more juice out of the move. Details: • Signal: $1.17 • Exit: $1.29 • Total Move Captured: +11.1% When both models (AI + Momentum) fire on the same ticker, you pay attention. Founder's Rate Access: Limited Spots available. Join the Hive via Link in Bio 🐝

0 · Reply

BullishBee Jan. 8 at 8:41 PM

🌊 Momentum Cycle Closed: $ANTX We entered at 11:23 AM and rode the volume into the afternoon. The Trade: 🔹 Entry: $1.14 🔹 Exit: $1.23 🔹 Gain: +7.5% Secured Consistency builds the account. Another green row in the ledger. Founder's Rate Access: Limited Spots available. Join the Hive via Link in Bio 🐝

0 · Reply

MrPendragon Jan. 8 at 5:31 PM

$ANTX Last couple of days were the "spring" in the Wyckoff accumulation phase, I sold 10k$ worth at 1.05 two days ago to test the market, it got gobbled up instantly. Now let's see this chagas disease PK data

0 · Reply

THSSKS Jan. 8 at 4:35 PM

$IPSC called this from the bottom. $ANTX im buying anything close to $1. They have approximately $2.26 cash per share and data for phase 1 Chagas’ disease in q1 coming

0 · Reply

OfficialStocktwitsUser Jan. 6 at 4:40 AM

$ANTX RSI: 30.30, MACD: -0.0098 Vol: 0.04, MA20: 1.13, MA50: 1.14 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

SuperGreenToday Dec. 31 at 5:52 PM

$ANTX

0 · Reply

SprintShares Dec. 26 at 4:58 PM

$ANTX Market structure is quietly punishing unfocused strategies. Efficiency initiatives must translate into measurable productivity. Momentum could expand quickly if milestones stop slipping. Durable value creation requires execution to catch up with vision.

0 · Reply

TheRealShortSqueezy Dec. 15 at 3:26 PM

$HYFT: Riding the AI Biotech Wave Into Its Next Stage of Growth With AI fueling a new era of biotech breakthroughs, MindWalk is perfectly positioned, merging deep tech and biology to accelerate discoveries the entire sector has been waiting for. 📞 Conference Call Coming Up As the call approaches, investors are looking for clarity on HYFT’s accelerating momentum. Key topics expected to be discussed include: ➖ Record Q2 revenue growth and margin expansion ➖ Updates on the GLP-1 + longevity programs and dengue vaccine progress ➖ Strategic direction heading into the mid-January JPM update 💰 Strengthened by September’s Strategic Move On Sept 15, MindWalk sold its Netherlands operations, unlocking over $14M. That capital is now being directed into HYFT’s core BioNative AI platform and wet lab programs. Communicated Disclaimer : https://tinyurl.com/58pvrf5j Sector Peers: $FATE $IGMS $ANTX $CABA

1 · Reply

Market Cap	29.87M
Revenue (ttm)	0.00
Net Income (ttm)	-51.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	101,400
Avg Vol	90,944
Day's Range	N/A - N/A
Shares Out	27.40M
Stochastic %K	29%
Beta	-0.03
Analysts	Sell
Price Target	$1.50